PRENATAL MATERNAL STEROID TREATMENT - EFFECT ON MORTALITY AND BRONCHOPULMONARY DYSPLASIA (BPD) IN EXTREMELY PREMATURE INFANTS
Dag Bratlid
Norway 
1 slide(s) – English – 2010-10-23
Background and aims: Prenatal steroids (PS) are considered important in the treatment of extremely premature infants. The study was undertaken to evaluate the impact of PS on mortality and BPD in a national cohort with a high rate of prenatal steroid tretment.
Methods: All 452 admitted infants with GA ? 30 weeks from a national cohort of infants with gestational age (GA) of 220 to 276 weeks and/or birth weight (BW) of 500 to 999 g were studied. 83 infants died and 376 infants who survived past day 28 were evaluated for development of BPD.
Results: Although infants with or without PS had similar GA and BW, no significant differences in mortality or development of BPD could be seen (Table 1).
| | | PS+ | PS- | p | | Entire cohort | 452 | 381* | 54 | | | GA (wks) | 26.2±1.7 | 26,1±1.7 | 26,3±1.5 | 0.398 | | BW (g) | 832±180 | 829±182 | 842±156 | 0.596 | | Died | 83 (18.4%) | 68 (17.8%) | 13 (24.1%) | 0.311 | | BPD cohort | 376 | 322# | 41 | | | GA (wks) | 26.4±1.5 | 26.4±1.6 | 26,7±1.6 | 0.257 | | BW (g) | 853±176 | 845±175 | 904±174 | 0.040 | | BPD | 170 | 148 (45,9%) | 19 (46.3%) | 0.963 | [Table 1]
* data missing for 17 infants # data missing for 13 infants
Conclusions: The study indicates that treatment with prenatal steroids have only minor effects on mortality and development of BPD in extremely premature infants.
Background and aims: Prenatal steroids (PS) are considered important in the treatment of extremely premature infants. The study was undertaken to evaluate the impact of PS on mortality and BPD in a national cohort with a high rate of prenatal steroid tretment.
Methods: All 452 admitted infants with GA ? 30 weeks from a national cohort of infants with gestational age (GA) of 220 to 276 weeks and/or birth weight (BW) of 500 to 999 g were studied. 83 infants died and 376 infants who survived past day 28 were evaluated for development of BPD.
Results: Although infants with or without PS had similar GA and BW, no significant differences in mortality or development of BPD could be seen (Table 1).
| | | PS+ | PS- | p | | Entire cohort | 452 | 381* | 54 | | | GA (wks) | 26.2±1.7 | 26,1±1.7 | 26,3±1.5 | 0.398 | | BW (g) | 832±180 | 829±182 | 842±156 | 0.596 | | Died | 83 (18.4%) | 68 (17.8%) | 13 (24.1%) | 0.311 | | BPD cohort | 376 | 322# | 41 | | | GA (wks) | 26.4±1.5 | 26.4±1.6 | 26,7±1.6 | 0.257 | | BW (g) | 853±176 | 845±175 | 904±174 | 0.040 | | BPD | 170 | 148 (45,9%) | 19 (46.3%) | 0.963 | [Table 1]
* data missing for 17 infants # data missing for 13 infants
Conclusions: The study indicates that treatment with prenatal steroids have only minor effects on mortality and development of BPD in extremely premature infants.
|
